Prashanth Gopalakrishna
About
Prashanth Gopalakrishna is a scholar working on Genetics, Hematology and Oncology.
According to data from OpenAlex, Prashanth Gopalakrishna has authored 28 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 15 papers in Hematology and 7 papers in Oncology. Recurrent topics in Prashanth Gopalakrishna's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Cancer Treatment and Pharmacology (6 papers). Prashanth Gopalakrishna is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Cancer Treatment and Pharmacology (6 papers). Prashanth Gopalakrishna collaborates with scholars based in Switzerland, United Kingdom and Italy. Prashanth Gopalakrishna's co-authors include Claire Harrison, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Francisco Cervantes, Vikas Gupta, Ruben A. Mesa, Srđan Verstovšek, Jason Gotlib, Tuochuan Dong and Ahmad Naim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.
In The Last Decade
Prashanth Gopalakrishna
28 papers receiving 596 citations
Peers
Prashanth Gopalakrishna
Elisabetta Gattoni Italy
Mei-Li Wen United States
Jeffrey Keats United States
Sara Dellasala United States
Emilie Leroy Belgium
А К Голенков Russia
Nabih Maslah France
Nadine Besson United States
Angela Volkert United States
J. Janssen Netherlands
Citations per year, relative to Prashanth Gopalakrishna Prashanth Gopalakrishna (= 1×)
peers
Elisabetta Gattoni
Countries citing papers authored by Prashanth Gopalakrishna
Since
Specialization
Citations
This map shows the geographic impact of Prashanth Gopalakrishna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prashanth Gopalakrishna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prashanth Gopalakrishna more than expected).
Fields of papers citing papers by Prashanth Gopalakrishna
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Prashanth Gopalakrishna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prashanth Gopalakrishna. The network helps show where Prashanth Gopalakrishna may publish in the future.
Co-authorship network of co-authors of Prashanth Gopalakrishna
This figure shows the co-authorship network connecting the top 25 collaborators of Prashanth Gopalakrishna. A scholar is included among the top collaborators of Prashanth Gopalakrishna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prashanth Gopalakrishna. Prashanth Gopalakrishna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ignatiadis, Michail, Carlos H. Barrios, François‐Clément Bidard, et al.. (2024). International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.. Journal of Clinical Oncology. 42(16_suppl). TPS1129–TPS1129.
2.
Blagden, Sarah P., Anne Hamilton, Linda Mileshkin, et al.. (2018). Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clinical Cancer Research. 25(5). 1472–1478.
3.
Ross, David M., Tamás Masszi, María Teresa Gómez‐Casares, et al.. (2018). Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. Journal of Cancer Research and Clinical Oncology. 144(5). 945–954.
4.
Verstovšek, Srđan, Jason Gotlib, Ruben A. Mesa, et al.. (2017). Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology & Oncology. 10(1). 156–156.
5.
Radich, Jerald P., François‐Xavier Mahon, Andreas Hochhaus, et al.. (2017). ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma Myeloma & Leukemia. 17. S314–S315.
6.
Mauro, Michael J., Carla Boquimpani, Yosuke Minami, et al.. (2017). Oral Asciminib (ABL001) vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Received ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): A Multicenter, Open-Label, Randomized, Phase 3 Study. Clinical Lymphoma Myeloma & Leukemia. 17. S315–S316.
7.
Gupta, Vikas, Srđan Verstovšek, Ronald Paquette, et al.. (2016). Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials. Blood. 128(22). 3118–3118.
8.
Verstovšek, Srđan, Vikas Gupta, Jason Gotlib, et al.. (2016). A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). Blood. 128(22). 3110–3110.
9.
Harrison, Claire, Jean‐Jacques Kiladjian, Florian H. Heidel, et al.. (2015). Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF). Blood. 126(23). 4060–4060.
10.
McMullin, Mary Frances, Claire Harrison, Dietger Niederwieser, et al.. (2015). The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Experimental Hematology and Oncology. 4(1). 26–26.
11.
Vannucchi, Alessandro M., Heinz Gisslinger, Claire Harrison, et al.. (2015). EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline. Blood. 126(23). 2817–2817.
12.
Oritani, Kenji, Shinichiro Okamoto, Tetsuzo Tauchi, et al.. (2015). A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis. International Journal of Hematology. 101(3). 295–304.
13.
Gupta, Vikas, Claire Harrison, Hans Carl Hasselbalch, et al.. (2015). Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood. 126(23). 825–825.
14.
Durrant, S. T. S., Arnon Nagler, Alessandro M. Vannucchi, et al.. (2015). An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. Blood. 126(23). 827–827.
15.
Durrant, Simon, Maya Koren‐Michowitz, David Lavie, et al.. (2014). HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF). Blood. 124(21). 710–710.
16.
Al‐Ali, Haifa Kathrin, et al.. (2014). Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib. Blood. 124(21). 1836–1836.
17.
Vahdat, Linda T., Agustin A. García, Charles L. Vogel, et al.. (2013). Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Research and Treatment. 140(2). 341–351.
18.
Raftopoulos, Harry, Joseph Aisner, Sanjay Goel, et al.. (2013). Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 31(15_suppl). e19145–e19145.
19.
Plummer, Ruth, T.R. Jeffry Evans, David Alan Anthoney, et al.. (2012). A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer.. Journal of Clinical Oncology. 30(15_suppl). 2552–2552.
20.
Vahdat, Linda T., Agustin A. García, Charles L. Vogel, et al.. (2012). Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study.. Journal of Clinical Oncology. 30(27_suppl). 121–121.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Elisabetta Gattoni Breakdown of academic impact, for papers by Mei-Li Wen Breakdown of academic impact, for papers by Jeffrey Keats Breakdown of academic impact, for papers by Sara Dellasala Breakdown of academic impact, for papers by Emilie Leroy Breakdown of academic impact, for papers by А К Голенков Breakdown of academic impact, for papers by Nabih Maslah Breakdown of academic impact, for papers by Nadine Besson Breakdown of academic impact, for papers by Angela Volkert Breakdown of academic impact, for papers by J. Janssen